Adventures with the β2-adrenoceptor Receptor: A Career Long Interest in Agonising One of the Most Widely Studied GPCRs

Authors

  • Robin A. Fairhurst Novartis Oncology Disease, Basel, CH-4056, Switzerland

DOI:

https://doi.org/10.2533/chimia.2024.483

PMID:

39221844

Keywords:

β2-adrenoceptor agonist, Asthma, COPD, Intrinsic efficacy

Abstract

Drug discovery is a multi-disciplinary effort in which groups with expertise in a range of areas combine in a unified way to achieve a common goal: to deliver a clinical candidate to evaluate a hypothesis for improving human health. As a medicinal chemist this environment has provided multiple opportunities to be involved in cross-discipline interactions that have been both rewarding and led to outcomes that would not have been possible without an intimate interdisciplinary curiosity. Within this article I aim to share some of my experiences with the β2-adrenoceptor that have fostered such synergistic relationships with several disciplines, but in particular with in vitro pharmacologists looking at different ways to stimulate this G protein-coupled receptor (GPCR). This interest now spans over a quarter of a century and has been intertwined with the delivery of three clinical candidates.

Downloads

Published

2024-08-21